Dyne Therapeutics, Inc.
DYN
$12.40
$0.161.31%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 73.03% | 83.12% | 27.52% | 210.52% | 27.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.46% | 69.67% | 7.83% | 52.11% | 68.61% |
| Operating Income | -43.46% | -69.67% | -7.83% | -52.11% | -68.61% |
| Income Before Tax | -34.37% | -61.31% | -0.31% | -48.57% | -71.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.37% | -61.31% | -0.31% | -48.57% | -71.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.37% | -61.31% | -0.31% | -48.57% | -71.63% |
| EBIT | -43.46% | -69.67% | -7.83% | -52.11% | -68.61% |
| EBITDA | -43.65% | -70.14% | -7.93% | -52.65% | -69.31% |
| EPS Basic | 19.11% | 2.28% | 35.12% | -3.25% | -47.65% |
| Normalized Basic EPS | 19.10% | 2.29% | 35.12% | -3.26% | -47.67% |
| EPS Diluted | 19.11% | 2.28% | 35.12% | -3.25% | -47.65% |
| Normalized Diluted EPS | 19.10% | 2.29% | 35.12% | -3.26% | -47.67% |
| Average Basic Shares Outstanding | 66.11% | 65.08% | 54.60% | 43.88% | 16.24% |
| Average Diluted Shares Outstanding | 66.11% | 65.08% | 54.60% | 43.88% | 16.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
